Highlights• Medical research funding in the United States is at an all-time low.• Diminished funding has affected kidney disease research more than other disease-defined research areas.20 million Americans have chronic kidney disease.
Newswise — Washington, DC (March 20, 2014) — Medical research funding from public and private sources is at an all-time low. A new Journal of the American Society of Nephrology (JASN) article discusses the effects of such funding constraints, with a focus on the plight of kidney research.
“The scientific research investment gap continues to widen, jeopardizing potential new insights into diseases and, more importantly, new cures,” said co-author Roy Zent, MD, PhD (Vanderbilt Medical Center). He and his colleagues noted that although the National Institutes of Health’s annual budget doubled from $13.7 to $26.9 billion per year between 1998 and 2003, it has failed to keep pace with inflation since 2003. Also, the percentage of funding for the National Institute of Diabetes and Digestive and Kidney Diseases and kidney-related research has continued to decrease while the percentage of funds to other institutes has experienced a steady increase. “With 20 million Americans affected by kidney disease, we can’t afford to delay clinical advances for our patients,” said Dr. Zent.
The authors stressed that health professional groups, patient organizations, government, industry, and others focused on improving kidney health must step up and support clinical and basic researchers. The American Society of Nephrology has developed a Career Development Grants Program to support investigators, and it has partnered with the FDA, through the Kidney Health Initiative, to create an opportunity for multidisciplinary specialties to advance kidney treatment, address patient safety, and develop therapies in a collaborative environment.
However, additional efforts are needed to make ongoing strides in kidney research and other areas of study. “Medical research and innovation are a critical component of the United States’ economic competitiveness within the global economy, and they directly feed the vitality of the country’s health care system. This is why we are raising awareness of the key role research plays in improving the lives of patients with kidney disease, and why are calling for broad support for medical research in the United States,” said Dr. Zent.
Study co-authors include Lisa Bryan, Tod Ibrahim, and Michael J. Fischer, MD.
Disclosures: The authors reported no financial disclosures.
The article, entitled “The Kidney Research Predicament,” will appear online at http://jasn.asnjournals.org/ on March 20, 2014.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 14,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
# # #